drug · antibody drug conjugate
trastuzumab emtansine
Marketedupdated 5mo agoby Genentech Inc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 4 investigational indications.
targets
Receptor tyrosine-protein kinase erbB-2Tubulin
all catalysts(14)
approval · 14
Feb 22, 2013
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Aug 19, 2013
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Aug 29, 2013
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Jul 11, 2014
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
May 29, 2015
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Apr 28, 2016
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Jul 25, 2016
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Sep 20, 2018
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Dec 18, 2018
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
May 3, 2019
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Sep 27, 2020
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Feb 2, 2022
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
May 14, 2025
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Mar 26, 2026
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Trials studying trastuzumab emtansine
- phase2A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
- phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- phase3A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- phase2Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- phase2HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
- phase3A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- phase3T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- phase2A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
News(4)
- Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBioThrough its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.biospace · 1mo ago
- Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerSacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.onclive · 4mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 4mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that